Diseases / Metabolic Syndrome
Metabolic Syndrome
DiseaseMetabolic syndrome is a cluster of cardiometabolic risk factors including abdominal obesity, dyslipidemia, hypertension, and hyperglycemia that together increase risks of cardiovascular disease and type 2 diabetes.
- Trials
- 2085
- Recruiting
- 176
- Completed
- 1276
- With results
- 184
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 2 | 2 | 1 | — | 12 | 1 | — | — | 3 | — | 21 |
| Phase 1 | 1 | — | — | — | 19 | 2 | 1 | — | 4 | — | 27 |
| Phase 1/2 | 4 | — | — | — | 19 | 1 | — | — | 1 | — | 25 |
| Phase 2 | 7 | 2 | — | 1 | 76 | 10 | 5 | — | 6 | — | 107 |
| Phase 2/3 | 2 | 1 | — | — | 28 | — | — | — | 3 | — | 34 |
| Phase 3 | 1 | 2 | 2 | 2 | 44 | 7 | 1 | 1 | 11 | — | 71 |
| Phase 4 | 9 | 4 | 1 | — | 86 | 13 | 1 | — | 24 | — | 138 |
| Not applicable | 95 | 37 | 13 | 39 | 756 | 28 | 19 | 7 | 170 | — | 1164 |
| Unknown | 55 | 32 | 5 | 14 | 236 | 7 | 7 | 2 | 139 | 1 | 498 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Metabolic Syndrome | 21 | 27 | 25 | 107 | 34 | 71 | 138 | 1164 | 498 | 2085 |
| Obesity | 8 | 10 | 10 | 24 | 4 | 16 | 27 | 363 | 150 | 612 |
| Insulin Resistance | — | 6 | 6 | 37 | 3 | 7 | 24 | 175 | 60 | 318 |
| Diabetes Mellitus | 2 | 2 | 5 | 14 | 1 | 6 | 10 | 97 | 78 | 215 |
| Hypertension | 1 | 4 | 5 | 14 | — | 7 | 20 | 91 | 56 | 198 |
| Cardiovascular Diseases | 2 | — | — | 11 | 1 | 2 | 9 | 89 | 78 | 192 |
| Overweight | 1 | 3 | 1 | 8 | 3 | 3 | 4 | 115 | 40 | 178 |
| Diabetes Mellitus, Type 2 | 1 | 2 | 2 | 14 | 4 | 9 | 13 | 81 | 43 | 169 |
| Motor Activity | — | — | — | 1 | 1 | 3 | 2 | 112 | 22 | 141 |
| Inflammation | — | 1 | 4 | 5 | 4 | 3 | 4 | 81 | 21 | 123 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Laval University | 24 | 1 |
| 2 | University of Copenhagen | 20 | 0 |
| 3 | Cairo University | 18 | 0 |
| 4 | University of Toronto | 17 | 0 |
| 5 | National Taiwan University Hospital | 16 | 0 |
| 6 | Lund University | 14 | 0 |
| 7 | Massachusetts General Hospital | 14 | 0 |
| 8 | University of Aarhus | 14 | 0 |
| 9 | Assistance Publique - Hôpitaux de Paris | 13 | 0 |
| 10 | University of California, Davis | 13 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Exercise | 85 |
| 2 | Metformin | 46 |
| 3 | Diet | 38 |
| 4 | Diet, Mediterranean | 19 |
| 5 | Bariatric Surgery | 16 |
| 6 | Pioglitazone | 16 |
| 7 | Fish Oils | 15 |
| 8 | Blood Specimen Collection | 14 |
| 9 | Control Groups | 14 |
| 10 | Standard of Care | 14 |
Evidence
- Results reported
- 14.4%184 of 1276 completed
- Published
- 16.6%212 of 1276 completed
- Primary endpoint met
- 26.3%66 of 251 analyses
- Median months to report
- 22.5
Documents disclosed
Trial profile
- Median enrollment
- 70
- Median duration
- 25.8months
- Countries
- 84
- Study sites
- 3472
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 40
- Phase 1
- 34
- Phase 1/2
- 64
- Phase 2
- 58
- Phase 2/3
- 101
- Phase 3
- 100
- Phase 4
- 60
- Not applicable
- 56
- Unknown
- 180
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Boston | United States | 53 |
| 2 | Toronto | Canada | 41 |
| 3 | Taipei | Taiwan | 37 |
| 4 | Québec | Canada | 35 |
| 5 | Seoul | South Korea | 32 |
| 6 | New York | United States | 28 |
| 7 | Aarhus | Denmark | 24 |
| 8 | Paris | France | 22 |
| 9 | Chicago | United States | 21 |
| 10 | Copenhagen | Denmark | 21 |
Terminations
- Terminated
- 69
- Withdrawn
- 34
- Suspended
- 10
- Stopped for recruitment
- 1.2%24 of 2085 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04910321 Withdrawn | Withdrawn | The study was terminated due to the COVID-19 situation. | 2029-12-31 |
| NCT07329088 Withdrawn | Withdrawn | The study was not funded. | 2029-01-31 |
| NCT02506946 Suspended | Suspended | Lack of funding | 2026-08-31 |
| NCT06351683 Terminated | Terminated | Recruitment not proceeding as planned. | 2026-04-01 |
| NCT05689710 Suspended | Suspended | Difficulties in enrollment and patient compliance | 2026-01-31 |
| NCT05884437 Suspended | Suspended | Prioritizing other studies | 2025-12-16 |
| NCT05305352 Withdrawn | Withdrawn | Due to less number of participants willing to participate. | 2025-07-31 |
| NCT05372445 Terminated | Terminated | Recruitment was discontinued due to Argentina severe socio-economic crisis, which significantly impacted hospital operations and research funding. The loss of financial support prevented further enrollment and coverage of clinical and lab assessments | 2025-07-31 |
| NCT04207424 Withdrawn | Withdrawn | Patients were selected but their very condition and the resulting comorbidities did not allow their inclusion. In addition, the health crisis prevented any bariatric operation of this complexity for an indefinite period. | 2025-05-31 |
| NCT05832190 Terminated | Terminated | end of ERC funding period | 2024-12-24 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Metabolic Syndrome trials on ClinicalTrials.gov →